PCI Biotech appoints Mr Ludovic Robin as Chief Business Officer
30 avr. 2020 03h54 HE
|
PCI Biotech Holding ASA
Oslo, Norway, 30 April 2020 - PCI Biotech announces the appointment of Mr Ludovic Robin, PharmD, MBA, as Chief Business Officer (CBO). Mr Robin will also serve as a member of PCI Biotech’s executive...
PCI Biotech: Invitation to Q1 2020 results presentation
28 avr. 2020 07h00 HE
|
PCI Biotech Holding ASA
Oslo, Norway, 28 April 2020 - PCI Biotech’s Q1 2020 interim report will be released on 6 May, 2020 at 07.00 CEST. The interim report and presentation will be made available on www.newsweb.no and on...
PCI Biotech Holding ASA publishes the Annual Report 2019
22 avr. 2020 02h00 HE
|
PCI Biotech Holding ASA
Oslo, Norway, April 22, 2020. The Board of Directors of PCI Biotech Holding ASA has approved the Annual Report 2019 and the report is attached. The Annual Report 2019 is also available on the...
PCI Biotech appoints Dr Amir Snapir as Chief Medical Officer
31 mars 2020 02h00 HE
|
PCI Biotech Holding ASA
Oslo, Norway, 31 March 2020 - PCI Biotech announces the appointment of Dr Amir Snapir, MD, PhD as Chief Medical Officer (CMO). Dr Snapir will also serve as a member of PCI Biotech’s executive...
PCI Biotech: US patent for the vaccine technology (fimaVacc) with a new important class of adjuvants
26 mars 2020 04h12 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 26 March 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces that the U.S. Patent and Trademark Office (USPTO) has informed the company that a...
PCI Biotech: Update on operational implications of the corona pandemic
25 mars 2020 05h06 HE
|
PCI Biotech Holding ASA
Oslo, Norway, 25 March, 2020: PCI Biotech (OSE: PCIB) has closely monitored potential implications on its short- and long-term operations following the latest development of the coronavirus pandemic....
PCI Biotech's fourth quarter and preliminary 2019 results
26 févr. 2020 01h00 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 26 February 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim fourth quarter and preliminary 2019 results. Please find enclosed the...
PCI Biotech: Invitation to fourth quarter and preliminary 2019 results presentation
19 févr. 2020 07h38 HE
|
PCI Biotech Holding ASA
Oslo, Norway, 19 February 2020 - PCI Biotech invites to a presentation of the company's fourth quarter and preliminary 2019 results on Wednesday 26 February 2020 at Oslo Cancer Cluster Innovation...
PCI Biotech: US patent granted for the vaccine technology (fimaVacc) in combination with cytokines
21 janv. 2020 02h00 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 21 January 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces that the U.S. Patent and Trademark Office (USPTO) has granted the company a US...
PCI Biotech to present Phase I fimaVacc results at ESMO Immuno-Oncology 2019
12 déc. 2019 02h00 HE
|
PCI Biotech Holding ASA
Oslo, Norway, December 12, 2019 PCI Biotech (OSE:PCIB), a clinical-stage company developing innovative therapeutics that address significant unmet medical needs, today announced that it will present...